Inovio Pharmaceuticals, 8-K (7.01, 8.01, 9.01): Regulation FD disclosure

INOVIO said the FDA granted accelerated approval for VOCERYQ to reduce surgery frequency in adults with recurrent respiratory papillomatosis, supported by a study in which 7 of 26 patients achieved a 12-month complete response; availability is expected in about 60 days.